Abstract:Decades ago, colorectal cancer was rarely diagnosed. Today, it is the fourth leading cause of cancer-related deaths worldwide, with nearly 90,000 fatalities each year. By analyzing single-cell data from tumor-bearing colorectal cancer model mice with Lphn1 knockout and wild-type Lphn1, we identified five key target genes for anticancer therapy: Ulbp1, Klrk1, Ccl6, Tlr4, Cd48, Prdm5, Vstm2a, Ret, Oas2, Hdac11 and Ptchd4, along with their corresponding cell types. Additionally, we discovered tumor-inhibiting cell subpopulations, including Cd244a_T_cells_subcluster_1, Cd48_Cd244a_NK_cells_subcluster_2, and C3_Macrophages_subcluster_1, which are potential candidates for therapeutic intervention. We propose that cancer-associated fibroblasts (CAFs) serve as the primary antigen presenters for MHC class I, providing antigens to macrophages, NK cells, and T cells to combat colorectal cancer. From a cellular perspective, the knockout of Lphn1 activates the anti-colorectal cancer functions of subpopulations of macrophages, NK cells, and T cells. Macrophages enhance antitumor immune activity by engaging the Ulbp1-Klrk1 receptor pair to activate NK cells. Additionally, macrophages activate downstream functions of T cells against colorectal cancer through CD48 signaling. After the knockout of Lphn1, macrophages are recruited by autocrine Ccl6 and Ccl6 secReted by CAFs. They exhibit high expression of Tlr4 and have the potential to transition into M1-type macrophages due to changes in their cellular state. After the knockout of Lphn1, the CAFs were reduced by half. CAFs, which are part of the cell network communication associated with tumor cells, typically play an immunosuppressive role. A reduction by half indicates that the immunosuppression in the Lphn1 knockout group has significantly decreased. This suggests that the efficacy of various cancer immunotherapy drugs can be significantly enhanced. In specific cell types, the four colorectal cancer-resistant transcription factors Irf7, Nr2f1 (with uncertain function), Bclaf1, and Irf2 co-localize with Tlr4, Cd48, Prdm5, and Oas2, respectively, and have been analyzed by pyscenic to interact and functionally contribute to the resistance against colorectal cancer. The four differential metabolic pathways between the Lphn1 group and the luc group are Arginine and proline metabolism, Histidine metabolism, Phenylalanine metabolism, and Riboflavin metabolism, with Arginine and proline metabolism being more active in the Lphn1 group and Histidine metabolism being more active in the luc group. These findings could open new avenues for the treatment of colorectal cancer and contribute to the development of personalized medicine.

LFA-1 knockout inhibited the tumor growth and is correlated with treg cells

Blocking LAIR1 signaling in immune cells inhibits tumor development

IL1R2 increases regulatory T cell population in the tumor microenvironment by enhancing MHC-II expression on cancer-associated fibroblasts

UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity

Antagonist anti-LIF antibody derived from naive human scFv phage library inhibited tumor growth in mice

Hepatocyte-derived FGL1 Accelerates Liver Metastasis and Tumor Growth by Inhibiting CD8+ T and NK Cells

FOXF1 inhibits invasion and metastasis of lung adenocarcinoma cells and enhances anti-tumor immunity via MFAP4/FAK signal axis

ImmunizationAntitumor Efficacy of Lentivector Tumor-Infiltrating T Cells and Enhances the Rescues the Effector Function of Blockade of Programmed Death-1 Pathway

Lactoferrin-containing Immunocomplex Mediates Antitumor Effects by Resetting Tumor-Associated Macrophages to M1 Phenotype.

Cutting Edge: LFA-1 Is Required for Liver NK1.1+TCRαβ+ Cell Development: Evidence That Liver NK1.1+TCRαβ+ Cells Originate from Multiple Pathways

Suppression of Tumorigenesis in LUAD by LRP1B Through Regulation of the IL-6-JAK-STAT3 Pathway.

Research on the Mechanism of Lphn1 Knockout in Inhibiting Colorectal Cancer

Loss of Trefoil Factor 1 Accelerates the Immune Response to Colorectal Cancer

Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation

TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis in mice

Fibrinogen Like Protein-1 Knockdown Suppresses the Proliferation and Metastasis of TU-686 Cells and Sensitizes Laryngeal Cancer to LAG-3 Blockade

Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR

Tumor cells inhibit the activation of ILC2s through up-regulating PD-1 expression

Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation and migration and is associated with dismal prognosis and immunity in lung squamous cell carcinoma

Abstract A088: Increase Lymphocyte Infiltration Overcomes Tumor Resistance to Checkpoint Blockade

LYG1 exerts antitumor function through promoting the activation, proliferation, and function of CD4 T cells.